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Flaviviral infections including dengue virus are an increasing clinical problem worldwide.
Dengue infection triggers host production of the type 1 IFN, IFN alpha, one of the
strongest and broadest acting antivirals known. However, dengue virus subverts host
IFN signaling at early steps of IFN signal transduction. This subversion allows unbridled
viral replication which subsequently triggers ongoing production of IFN which, again,
is subverted. Identification of downstream IFN antiviral effectors will provide targets
which could be activated to restore broad acting antiviral activity, stopping the signal
to produce endogenous IFN at toxic levels. To this end, we performed a targeted
functional genomic screen for IFN antiviral effector genes (IEGs), identifying 56 IEGs
required for antiviral effects of IFN against fully infectious dengue virus. Dengue IEGs
were enriched for genes encoding nuclear receptor interacting proteins, including HELZ2,
MAP2K4, SLC27A2, HSP90AA1, and HSP90AB1. We focused on HELZ2 (Helicase
With Zinc Finger 2), an IFN stimulated gene and IEG which encodes a promiscuous
nuclear factor coactivator that exists in two isoforms. The two unique HELZ2 isoforms
are both IFN responsive, contain ISRE elements, and gene products increase in the
nucleus upon IFN stimulation. Chromatin immunoprecipitation-sequencing revealed that
the HELZ2 complex interacts with triglyceride-regulator LMF1. Mass spectrometry
revealed that HELZ2 knockdown cells are depleted of triglyceride subsets. We thus
sought to determine whether HELZ2 interacts with a nuclear receptor known to regulate
immune response and lipid metabolism, AHR, and identified HELZ2:AHR interactions
via co-immunoprecipitation, found that AHR is a dengue IEG, and that an AHR ligand,
FICZ, exhibits anti-dengue activity. Primary bone marrow derived macrophages from
HELZ2 knockout mice, compared to wild type controls, exhibit enhanced dengue
infectivity. Overall, these findings reveal that IFN antiviral response is mediated by HELZ2
transcriptional upregulation, enrichment of HELZ2 protein levels in the nucleus, and
activation of a transcriptional program that appears to modulate intracellular lipid state.
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IEGs identified in this study may serve as both (1) potential targets for host directed
antiviral design, downstream of the common flaviviral subversion point, as well as (2)
possible biomarkers, whose variation, natural, or iatrogenic, could affect host response
to viral infections.
Keywords: interferon, interferon effector gene (IEG), genes that are required for IFN-mediated suppression of virus
INTRODUCTION
Adequate therapy is lacking for many clinically relevant flaviviral
infections, including dengue virus (DENV), Zika virus (ZIKV),
and yellow fever virus (YFV; Acosta and Bartenschlager, 2016;
Haug et al., 2016; Nishino et al., 2016). Viral pathology in
humans is attributed to both direct consequences of infection
and host mediated inflammation (Haug et al., 2016; Kuczera
et al., 2016; Valadao et al., 2016). Direct acting antivirals, or
therapeutics that specifically inhibit viral replication, have been
developed against several viruses [e.g., human immunodeficiency
virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV)],
but are limited by virus-specific activity, development lag time
and cost, potential for development of resistance, and lack of
effect on pathologic host inflammation. An alternate class of
antivirals, host directed antivirals (HDAVs), targets host factors
to suppress viral dependency factors or stimulate viral restriction
factors, usually modulating a broader antiviral defense system
(Acosta and Bartenschlager, 2016). This approach has the benefits
of (1) potential activity against many viruses, (2) consolidation
of development time/cost, (3) generally lower likelihood of
emerging resistance, and (4) potential to restore effective host
inflammatory response, leading to natural endpoints including
negative feedback that will limit excess, ineffective inflammatory
stimuli. For these reasons, investigations have focused on
exploiting antiviral properties of the host protein interferon alpha
(IFN) in a DENV/human cell line model, toward identification
of preclinical leads for broad-acting HDAV development. While
the antiviral properties of IFN have been known since the
1950s (Isaacs and Lindenmann, 1957), clinical efficacy of IFN
is limited due to viral subversion of IFN antiviral effects by
many viruses (Figure 1A). By contrast, activation of the IFN
pathway downstream of viral subversion might restore host
antiviral activity and also limit excess inflammation that is
likely triggered by lack of complete IFN signal transduction.
To identify the downstream effectors of IFN antiviral activity,
we applied a functional genetic approach to DENV because
an estimated 3.6 billion of the global population of 7.4 billion
people (49%) live in regions at risk for infection, and DENV
endemicity is spreading (Wilder-Smith and Gubler, 2008; Louis
et al., 2014; Messenger et al., 2014; Butterworth et al., 2016).
There is currently no effective treatment for DENV infection,
with clinical illness ranging from mild arthralgias to fatal
hemorrhagic shock (Horstick et al., 2015). Furthermore, factors
predicting likelihood of severe DENV/DENV shock syndrome
remain unclear, though repeat infection with antibody dependent
enhancement and coinfection with other viruses may contribute
to pathogenicity (Halstead, 2015; Perdigao et al., 2016). Efforts
to develop an effective vaccine are progressing, but have been
challenging (Kirkpatrick et al., 2016; Lourenco and Recker,
2016).
We have previously described a whole genome RNAi screen
in which we used fully infectious HCV in human Huh7.5.1
hepatocytes to identify 120 IFN effector genes (IEGs), or genes
required for the antiviral effect of IFN against HCV (Fusco
et al., 2013). We here tested knockdown of those same 120
HCV IEGs for rescue of fully infectious DENV New Guinea C 2
strain (NGC2) from IFN in HeLa cells, which were selected for
tractability (Figure 1B). Building upon our prior studies using
a whole genome RNAi screen, here we extend prior work by
identifying the functional importance of a novel IFN stimulated
helicase and nuclear receptor co activator, HELZ2 (Surapureddi
et al., 2002; Tomaru et al., 2006).
RESULTS
Screen for DENV IEGs
We aimed to identify human genes required for IFN-mediated
suppression of DENV, or DENV interferon effector genes (IEGs).
We defined positive hits as those genes for which knockdown
led to 1.5-fold or more increase of percent infection, compared
to negative controls, for 2 or more unique siRNAs. We found
that 56 of the 120 HCV IEGs were also DENV IEGs, required
for full antiviral effects of IFN against DENV (Datasheet S1,
Figures 1C,D). To further understand how IFN suppresses
virus, we then used a bioinformatics approach to look for
common pathways among the DENV/HCV IEGs and found
enrichment for factors related to nuclear receptors, or ligand-
activated transcription factors, including peroxisome proliferator
associated protein alpha (PPARα) and aryl hydrocarbon receptor
(AHR; Figure 1E). The DENV/HCV IEGs related to nuclear
receptors included HELZ2 (Helicase With Zinc Finger 2), a
poorly characterized nuclear receptor co-factor (Surapureddi
et al., 2002; Tomaru et al., 2006), and nuclear receptor chaperones
(HSP90AA1 and HSP90AB1), as well as other host factors
described to interact with nuclear receptors (MAP2K4, SLC27A2;
Meyer and Perdew, 1999; Bell and Poland, 2000; Hirai et al.,
2007; Lebsack et al., 2010; Ahn et al., 2011; Garcia-Fuster et al.,
2012; van Steenbeek et al., 2013; Chang et al., 2014; Tsuji et al.,
2014; Figures 1C,D). Because HELZ2 is an IEG (required for
full IFN antiviral effects), an ISG (upregulated by IFN at the
mRNA level), and a helicase, therefore possibly serving as amulti-
gene regulator, it seemed likely that HELZ2 was truly required
for IFN activity, so we then focused on the mechanism through
which HELZ2 mediates IFN antiviral effects (Lanford et al., 2006;
Feld et al., 2007; Sarasin-Filipowicz et al., 2008; He et al., 2010;
Fusco et al., 2013). Of note, humans express two HELZ2 isoforms
(Tomaru et al., 2006), both of which were targeted by the siRNAs
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FIGURE 1 | Targeted Dengue Interferon Effector Screen Identifies 56 DENV-HCV IEGs, including nuclear receptor pathway factors. (A) IFN signals
through IFNAR, JAK1, TYK2, STAT1/2 to activate transcription of IFN stimulated genes, including HELZ2. HELZ2 is a nuclear receptor co-activator and a helicase. (B)
A targeted RNAi screen was performed to identify host factors required for interferon’s antiviral activity against DENV, or DENV IFN effector genes (DENV IEGs). HeLa
cells were reverse transfected with 4 unique siRNAs for each of 120 HCV IEGs, followed by 48 h incubation, treatment with IFN, then infection with DENV2, followed
by 48 h incubation then staining, imaging, and quantitative analysis. (C) Raw Images from DENV IEG screen. HeLa cells were transfected with indicated siRNA,
processed as in (B), then stained with anti-DENV antibody (green) or Hoechst nuclear stain (blue) and imaged for quantitative analysis. Cell count and percent infection
are indicated on 10x images. (D) Rank plot of mean fold rescue for all screened siRNA duplexes. Fold rescue above 1.5 was considered positive. Y axis indicates
mean fold rescue, X axis indicates rank of rescue. (E) Bioinformatic analysis of DENV IEGs identified two nuclear receptor pathways, the aryl hydrocarbon receptor
pathway and the PPARα/RXR pathway.
used in these assays. No mechanistic difference between isoforms
has been described to date.
Out-of-Screen Confirmatory Studies
We then confirmed IEG status for screen hits HELZ2,
HSP90AA1, and HSP90AB1, verifying that RNAi-mediated
knockdown of each target gene led to rescue of DENV from
IFN in HeLa cells outside of screening conditions (Figure 2A).
We next examined the role of these genes in IFN-mediated
DENV suppression in hepatocytes, a clinical target cell for DENV
infection (Couvelard et al., 1999; Limonta et al., 2007; Aye et al.,
2014; Povoa et al., 2014; Figure 2B). RNAi-mediated knockdown
of HELZ2 led to DENV rescue from IFN in both HeLa cells
and hepatocytes. Furthermore, hepatocytes stably transduced
with shRNA against HELZ2, vs. vector control, also displayed
reproducible rescue of DENV from IFN, though the DENV-
rescue phenotype was more pronounced at lower doses of IFN,
compared to HeLa cells (Figures 2C,D).
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FIGURE 2 | DENV IEG Screen Hits Confirmation. (A) HeLa Cell Out-of-Screen DENV IEG Confirmation. RNAi mediated knockdown of select DENV IEG screen
hits confirmed rescue of DENV from IFN (HeLa Cells, n = 3–5). (B) IEG Phenotype Evaluation in a more clinically relevant cell type: hepatocytes. Huh7.5.1 cells were
transfected with indicated siRNA followed by treatment with IFN, then infection with DENV, and staining, quantitative imaging. (C) Stable HELZ2 knockdown cells
exhibit IFN resistance. Huh7.5.1 cells stably transduced with vector control (APM), shRNA targeting HELZ2 long and short isoforms (85 s) or long isoform only (91)
were evaluated for IFN resistance. HELZ2 knockdown cells exhibit IFN resistance compared to vector transduced controls. For (A–C), cells were treated with IFN then
infected with DENV, followed by staining for DENV and nucleus, then quantitative microscopy for percent infection. Stars indicate significant differences by two-tailed
t-tests, unequal variance. (D) Knockdown shRNA target schematic.
Validation of Target Gene Knockdown at
mRNA and Protein Level
HELZ2 was then selected for validation of gene-target
knockdown. Validation of long and short isoform protein
knockdown by four unique HELZ2 siRNAs was performed
using western blot (Figures 3A–C). Validation of mRNA
knockdown by four unique siRNAs was performed using qRT
PCR (Figure 3D), and revealed ∼75% or more fold knockdown
of HELZ2 by each unique siRNA duplex.
Mechanism of HELZ2 IFN Effector Function
Activation
Based on genomic sequence information from the UCSC genome
browser, we identified different transcription start sites for the
two isoforms of HELZ2, indicating that the unique HELZ2
isoforms are activated by distinct promoters (Figure 4C). We
generated unique luciferase promoter reporters for each of the
HELZ2 isoform promoters (Figure 4C), and examined isoform-
specific response to IFN stimulation in hepatocytes (Figure 4A,
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FIGURE 3 | Validation of HELZ2 knockdown in HeLa cells at the mRNA and protein levels. HeLa cells were transfected with four unique siRNAs targeting
HELZ2 (h1-4), or non-targeting control (nt), followed by 48 h incubation, then IFN treatment for 24 h, then protein or RNA harvest. Quantification of HELZ2 protein,
normalized to actin, from a representative western blot is shown for HELZ2 long isoform (A), short isoform (B), with western blot (C). Non transfected (null) sample is
indicated by n. qRT PCR was used to validate HELZ2 mRNA knockdown (D). *p < 0.05 compared to control.
Figures S1A–D), and found that both HELZ2 isoform promoters
are activated by IFN, with slightly greater activation of the
long vs. short isoform. We repeated these promoter reporter
experiments in HeLa cells, and noted much lower IFN activation
of both HELZ2 isoforms in HeLa cells compared to hepatocytes
(Figure 4B, Figures S1E–H). Search of the HELZ2 promoter
sequences revealed the presence of two distinct ISREs in the
HELZ2 long (beta) isoform promoter and no ISREs in the
HELZ2 short (alpha) isoform promoter (Tsukahara et al., 2006;
Datasheets S2 and S5). Of note the four unique ISRE sequences
detected in the HELZ2 promoter were slightly different from
published ISRE sequences, and might therefore be considered
unique ISREs (Tsukahara et al., 2006).
We also attempted to examine the effect of IFN stimulation
on isoform-specific mRNA upregulation, using isoform specific
HELZ2 primers. Though there was a trend toward the long
isoform of HELZ2 being more IFN-responsive than short-
isoform HELZ2 (Figure 4D), results were highly variable,
limiting interpretability. We next examined the effect of
IFN on HELZ2 protein levels and localization, using cellular
fractionation followed by western blot. We found that, in
hepatocytes, HELZ2-long isoform is detectable only upon
IFN stimulation, whereas HELZ2-short isoform is detected in
the absence of IFN, but upregulated upon IFN stimulation
(Figures 4E–I, Figure S1). Of note, the antibody used in our
HELZ2 protein analyses binds an epitope that is present in
both HELZ2 isoforms, and is therefore not isoform specific.
However, we were able to detect unique bands at roughly 200
and 290 kDa using Western blot, consistent with the long and
short HELZ2 isoforms, respectively. In contrast to hepatocytes,
HeLa cells displayed detectable HELZ2-short protein, but no
detectable HELZ2-long protein, using the abcam anti-HELZ2
Ab (ab129781). In HeLa cells, HELZ2-short protein was not
upregulated by IFN (data not shown). This decreased protein
expression and lack of protein IFN-responsiveness of HELZ2 in
HeLa cells, compared to Huh7.5.1 s, could explain in part the
weaker IEG phenotype of HELZ2 in HeLa compared to Huh7.5.1
cells. HeLa cells, have, however, been found to express mRNA
for both HELZ2 long and short isoforms (Tomaru et al., 2006),
indicating that HeLa vs. hepatocyte (cell to cell) variation in
HELZ2 protein expression levels may be at the translational level,
or could be due to limitation of the antibody we used.
Lifecycle Assays
In order to determine the lifecycle stage at which HELZ2
knockdown enhances DENV infection, we then performed a
series of lifecycle assays in human hepatocytes, comparing
infection in HELZ2 knockdown (85) vs. vector control (APM)
cells (Datasheet S3). To assess early infection, we used high
sensitivity RNA in situ hybridization 90 min following infection,
according to published methods (Savidis et al., 2016). In this
assay, we found increased infection levels in cells with HELZ2
knockdown (85) vs. vector controls (APM; Figure S2). We tested
HELZ2 knockdown effect on DENV RNA levels at a later time
point (24 h post infection) using qRT PCR. These experiments
revealed enhancedDENVRNA, both in the presence and absence
of IFN pretreatment, in HELZ2 knockdown cells vs. vector
controls (Figure S3). To complement our immunofluorescence
data, we tested effect of HELZ2 knockdown on DENV protein
levels using western blot. Western blot experiments revealed
an enrichment of DENV protein in HELZ2 knockdown cells,
compared to vector controls (Figure S4). Finally, to determine
the effect of HELZ2 knockdown on viral release into supernatant,
we performed supernatant plaque assays. While these results
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FIGURE 4 | HELZ2 long (beta, v1) and short (alpha, v2) isoforms are both IFN responsive. (A,B) HELZ2 alpha, beta promoter activation. Huh751 or HeLa cells
were transiently transfected with plasmids containing HELZ2v1 (beta, long isoform) or HELZv2 (alpha, short isoform) promoter with luminescence reporter. Cells were
treated with medium, IFN (dose indicated) or virus for 24 h, followed by development and luminescence read. Virus used was JFH1 HCV in Huh751 s and NGC2
DENV in HeLas. (A) IFN led to greater HELZ2 v1/beta than v2/alpha promoter activation in Huh7.5.1 human hepatocytes. (B) HeLa IFN response is attenuated
compared to Huh7.5.1 cells. Virus does not affect promoter response. (C) Promoter reporter schematic. The top purple lines indicate two unique HELZ2 promoters,
with different transcription start sites for the two HELZ2 isoforms identified based on genomic sequence information from the UCSC genome browser. The lower blue
schema represent the two unique luciferase promoter reporters generated for each of the HELZ2 isoform promoters. (D) HELZ2 isoform specific mRNA expression.
Response of HELZ2 mRNA to IFN time course was measured using isoform-specific primers and qRT PCR. (E–H) HELZ2 long (v1/alpha) and short (v2/beta) isoform
proteins are upregulated by IFN but not the PPARα agonist fenofibrate. (E) Huh7.5.1 cellular compartments were fractionated followed by western blot (wb) for
compartment specific HELZ2 expression analyses after 24 h stimulation with medium (M), IFN 1,600 IU/ml (I), or 10 um fenofibrate (F). Experiment was performed
thrice and a representative WB is shown (E). HELZ2 long isoform was detected between 420 and 247 kDa bands at highest levels during IFN treatment, with IFN
induction in both nuclear and non-nuclear compartments. HELZ2 short isoform protein was also enhanced by IFN, most significantly in the nuclear compartment.
(F,G) Representative WB results from e. were quantified for each compartment (x axis), with y axis indicating fold increase above background, which was set to 1.
mem, membrane; nuc, nucleus; chr, chromatin; cyt, cytoplasm; ske, cytoskeleton. (H,I) Pooled quantitative results for three compartment—specific HELZ2 WBs,
including (E) are shown for HELZ2 long (H) and short (I) isoforms. Raw data for each pooled experiment is presented in Datasheets S2 and S5.
exhibited significant variability, for each experiment (n = 3)
supernatant from HELZ2 knockdown cells generated more
plaques than supernatant from vector controls (Figure S5).
Overall, these results are consistent with a role for HELZ2 in
IFN-mediated suppression of DENV at a post-entry step. These
findings are consistent with our results for HELZ2 in control
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of HCV, where we also found that HELZ2 activity occurred
post-entry (Fusco et al., 2013).
Nuclear Receptor Interactions
We then sought to determine which, if any, nuclear receptor
is the mediator of HELZ2-IFN antiviral effects. We initially
examined PPARα, as there is some data supporting an antiviral
role for PPARs (Arnold et al., 2007; Hanley et al., 2010; Wakui
et al., 2010; Goldwasser et al., 2011; Hanley and Viglianti,
2011; Huang et al., 2011; Yoon et al., 2011; Sehgal et al.,
2012). PPARα knockdown did rescue DENV from IFN in HeLa
cells in our screen, but this result did not reproduce in HeLa
cells outside of screening conditions (Datasheet S1, Figure 5A).
However, PPARα knockdown did rescue DENV from IFN in
Huh7.5.1. cells, as did knockdown of two other nuclear receptor
family genes, MAP2K4 and SLC27A2 (Figure 5B). The PPARα
ligand fenofibrate did suppress proportionate HCV infection, in
hepatocytes, and proportionate DENV infection, in HeLa cells,
but it did so only with significant cytotoxicity, arguing against
a meaningful antiviral effect (Figure S6). IFN treatment did not
upregulate PPARα mRNA or mRNA of the PPARα target gene,
CPT1, though treatment with positive control fenofibrate did,
albeit weakly, in the Huh7.5.1 cell line (Figure S7). Overall,
these findings did not support a clear role for PPARα as the
major HELZ2-IFN nuclear receptor. To better understand the
mechanism of HELZ2 antiviral effects, we therefore turned our
attention to identifying additional factors that interact with
HELZ2 during IFN stimulation.
DNA Interactions
The HELZ2 sequence contains a Superfamily I DNA and/or
RNA helicase domain, raising the possibility that HELZ2 may
regulate a specific subset of genes. However, direct HELZ2-
DNA interactions have not been characterized. Because HELZ2
protein levels appear to increase in the nucleus upon IFN
stimulation (Figure 4E), we hypothesized that HELZ2 may bind
FIGURE 5 | PPARα does not appear to be the HELZ2-IFN Nuclear Receptor. (A) HeLa cells were transfected with four unique siRNAs targeting PPARα, without
any significant rescue of DENV from IFN as measured by percent infected cells, using IF as in Figure 1. (B) Huh7.5.1 cells were transfected with four unique siRNAs
targeting PPARα, and two of four siRNAs led to significant rescue of DENV from IFN. Knockdown of two other nuclear-receptor family genes, MAP2K4 (map) and
SLC27A2 (s) led to rescue of DENV from IFN for four of four unique siRNA duplexes. *p < 0.05 compared to control.
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a unique DNA population in the presence of IFN. To test
this hypothesis we performed chromatin immunoprecipitation
sequencing (CHiP seq), using HELZ2 immunoprecipitation (IP)
in human hepatocytes in the presence and absence of IFN.
Because predicted sites of HELZ2-DNA interaction during IFN
stimulation in hepatocytes were unknown, we used H3K27
immunoprecipitation of ActA2 enhancer sites as a positive
control for successful chromatin immunoprecipitation. These
experiments revealed that HELZ2 bound a unique population
of DNA in the presence, but not absence, of IFN. DNA
bound by HELZ2 uniquely in the presence of IFN included
closest genebody [Transcription Start Site (TSS) to transcription
termination site (TTS), including all introns]/enhancer site for
LMF1 (Lipase Maturation Factor 1), which encodes a chaperone
protein that activates vascular lipases which themselves regulate
triglyceride maturation and processing (Figure 6A; Peterfy,
2012). Because we had identified HELZ2 interactions with
lipid regulators, and HELZ2 is known to interact with nuclear
receptors that regulate intracellular lipid state, we proceeded to
examine the effect of HELZ2 expression on intracellular lipid
state. It is important to note that DENV infection has been
found to both require host lipids and to influence host lipid
state, in clinical infection and in in vitro studies (Villar-Centeno
et al., 2008; Heaton and Randall, 2010, 2011; Heaton et al., 2010;
Gutsche et al., 2011; Duran et al., 2015; Martin-Acebes et al.,
2016). Thus we hypothesized that IFN-mediated activation of
HELZ2, and its downstream gene targets, could effectively flip
a switch, converting host intracellular lipid state from “pro” to
“anti” viral.
Role in Intracellular Lipid Processing
We treated Huh7.5.1 cells with IFN or mock, then collected
supernatant and intracellular lysate for mass spectrometry (MS)
for high resolution lipid analysis (Rhee et al., 2011, 2013).
Supernatant samples revealed limited variability among cell
types, but intracellular lysate samples revealed major differences
for several lipids when comparing HELZ2 knockdown vs. vector
control cells. These differences included a highly significant
decrease in the triglyceride TAG 54:6 (number of carbons in
the lipid acyl chain: number of double bonds in the lipid
acyl chain; Figure 6B). TAG54.6 a representative lipid, showing
some of the most striking change comparing knockdown cells
to vector controls, among many TAGs which were lower in
HELZ2 knockdown cells vs. vector controls (Datasheet S4).
Based on our findings that (1) HELZ2 knockdown cells have
low triglyceride levels and (2) HELZ2 CHiP seq detected
HELZ2:LMF1 interaction, we postulated that HELZ2 must
interact with a lipid-regulating nuclear receptor. Since we had
not found strong evidence supporting a role for PPARα as
the HELZ2-IFN NR, we explored previously published datasets
supporting the role of other NRs as potential regulators of
the immune activation state and intracellular lipid status. In
this search we found that the NR AHR fit these criteria. AHR
was also the only other known ligand-activated transcription
factor/nuclear receptor identified by bioinformatics analysis of
our DENV IEG list (Figure 1E). We thus proceeded to explore a
possible role of AHR as an interferon effector/HELZ2 interactor.
Re-Examination of HELZ2—NR Interactions: Aryl
Hydrocarbon Receptor
AHR knockdown in HeLa cells rescued DENV from IFN for
three of four siRNA duplexes tested (Figure 7A). In hepatocytes,
AHR knockdown rescued DENV from IFN for the same
three siRNA duplexes that rescued DENV from IFN in HeLA
cells, identifying AHR as a HeLa and hepatocyte DENV
IEG (Figure 7B). AHR mRNA (Figures 7C,D) and protein
knockdown (Figure 7E) were validated in HeLa cells. We then
proceeded to look for evidence of HELZ2: AHR protein: protein
interactions. Using HELZ2 Ab for immunoprecipitation (IP), it
was possible to detect both HELZ2 and AHR, but not isotype
control, by immunoblot (IB). Conversely, using AHR Ab for
immunoprecipitation (IP), it was possible to detect both AHR
and HELZ2, but not isotype control, by IB. The HELZ2:AHR
interaction appeared to be conserved during treatment with both
IFN and the AHR ligand FICZ (6-Formylindolo(3,2-b)carbazole)
(Figures 7F,G). We next tested FICZ, which is a strong
AHR ligand, and ITE (2-(1′H-indole-3′-carbonyl)-thiazole-4-
carboxylic acid methyl ester), a weak AHR ligand, for antiviral
effects against DENV, using the same pretreatment model used
in our IFN experiments. Interestingly, FICZ, but not ITE,
pretreatment of hepatocytes led to a 40% reduction of percent
DENV infected cells (Figure 8) withminimal cytotoxicity (Figure
S8). Furthermore, FICZ did potentiate the antiviral dose of
submaximal IFN, though the dynamic range of these experiments
was limited (Figure 8). To determine whether the antiviral effect
of an AHR ligand was HELZ2 dependent, we then repeated
the FICZ/ITE antiviral experiments in hepatocytes with stable
knockdown of HELZ2-long andHELZ2 both isoforms and found
that HELZ2 knockdown does trend toward abrogation of the
anti-DENV effects of FICZ though this effect was not statistically
significant (Figures S9, S10). Because FICZ activates AHR, which
interacts with HELZ2, and both AHR and HELZ2 knockdown
are associated with a decrease in TAGs, we hypothesized that
FICZ antiviral effects may be due to a change in intracellular
lipid composition. To test this hypothesis, we measured TAG
levels in hepatocytes treated for 24 h with FICZ vs. DMSO using
two separate methods (Datasheet S3, Supplemental Methods
File). For the first method, we treated human hepatocytes with
FICZ at the dose we found to have the greatest antiviral effect
(Figure 8C, 920 um), vs. equal volume of DMSO, followed by
a commercial assay for crude measurement of triacylglycerols
(TAGs; BioVision K622). Using this assay, we did not identify
any enhancement (or decrease) of TAGs during FICZ treatment,
compared to DMSO (Figure S11A). At the same time, we treated
human hepatocytes with FICZ (920 um), vs. equal volume of
DMSO and harvested intracellular lysate for high content mass
spectrometry, a much more sensitive assay for TAG levels, and
also the technique used for the HELZ2 knockdown metabolite
studies presented above (Figure 6B). Interestingly, these studies
revealed that FICZ treatment does enhance the levels of a subset
of TAGs which are also decreased by HELZ2 knockdown (Figure
S11, Datasheet S4). This effect was most significant for TAG 58:9
and TAG 60:10. We have included the complete TAG datasets for
both HELZ2 knockdown cells vs. vector controls as well as FICZ
vs. DMSO (Datasheet S4).
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FIGURE 6 | HELZ2 CHiP seq and Metabolomics identify HELZ2 as a lipid regulator. (A) CHiP seq to identify DNA bound by HELZ2 during IFN stimulation in
hepatocytes. Chromatin immunoprecipitation was performed using anti-HELZ2 antibody on Huh7.5.1 human hepatocyte nuclear extracts following 24 h treatment
with IFN. Sequencing of DNA pulled down by anti-HELZ2 revealed enrichment for LMF1 transcription start site region sequences in the presence, but not absence, of
IFN. LMF1 encodes lipase maturation factor 1, a protein involved in the maturation and transport of lipoprotein lipase through the secretory pathway. The plot
indicates the chromasome location of enriched sequences detected by chromatin IP, harvested from cells with (top) and without (bottom) IFN treatment, on the x axis,
and coverage density, or quantity of DNA detected per nucleotide, on the y axis. The vertical line indicates the location of the TSS for LMF1, and the annotated Sox8
TSS is within 1 kb. (B) Metabolomics to determine the lipid profile of HELZ2 knockdown cells. Huh7.5.1 hepatocytes stably transduced with lentivirus containing
vector control (AP), shRNA targeting HELZ2 long and short isoforms (85) or shRNA targeting HELZ2 long isoform only (91) were treated with medium (M) or IFN (I)
followed by intracellular lipid extraction and analysis using mass spectrometry. HELZ2 knockdown cells were found to contain a highly significant decrease in the
triglyceride TAG 54:6 (number of carbons in the lipid acyl chain: number of double bonds in the lipid acyl chain), compared to vector controls, both in the presence
and absence of IFN treatment. In the box, the central line is the median, the lower margin of the box is the first quartile, the upper margin of the box is the third
quartile. The upper whisker extends from the hinge to the highest value that is within 1.5*IQR of the hinge, and the lower whisker extends from the hinge to the lowest
value that is within 1.5*IQR of the hinge.
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FIGURE 7 | AHR is an IFN Effector Gene and Interacts with HELZ2. RNAi-mediated knockdown of AHR with four unique siRNAs leads to weak but consistent
rescue of DENV from IFN in HeLa cells (A) and Huh7.5.1 hepatocytes (B). (C) Knockdown of AHR by the four unique siRNAs from (A) was validated at the protein
level using western blot (C) with quantification (D) and at the mRNA level using qRT PCR (E). (F) Co-immunoprecipitation of AHR with HELZ2 (H) and AHR (A)
antibodies and isotype control (I) was performed in Huh7.5.1 cells treated with IFN 1,600 IU/ml × 24 h or mock, followed by immunoblot for AHR. Load controls (Ld)
were run in parallel, and immunoblotted for AHR and actin (G). Co-immunoprecipitation was repeated in the setting of mock (M), IFN 1,600 IUml (I), or the AHR
agonist FICZ 0.9 um (F) × 24 h, using HELZ2 and AHR antibodies for IP, followed by HELZ2 and AHR immunoblot. Load controls were stained for HELZ2, AHR, and
actin. Ladder is indicated by L. *p < 0.05 compared to control.
Finally, to determine whether our findings might be relevant
in in vivo models, HELZ2 knockout mouse (Yoshino et al.,
2014) primary bonemarrow derivedmacrophages (BMDM)were
tested for DENV infectivity, compared to primary BMDM from
wild type (WT) controls. Consistent with a role for HELZ2 in
IFN-mediated suppression of DENV, these cells exhibited both
enhanced DENV infection and IFN resistance, compared to age
matched wild type controls (Figure 9). Furthermore, wild type,
but not knockout, mice exhibited enhanced sensitivity to murine,
vs. human, IFN as measured by percent infection in the presence
of IFN treatment (Figure S12).
DISCUSSION
Roughly half of the world population lives in regions at risk for
DENV infection, and medical countermeasures for DENV are
lacking. Furthermore, factors predicting severe DENV remain
unclear. We have here attempted to help clarify which host
factors participate in the IFN-mediated response to DENV. Our
hope is that these factors, the DENV IEGs, may serve as (1)
possible eventual targets for host directed antiviral design and/or
(2) candidate biomarkers for study in variable DENV clinical
outcomes.
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FIGURE 8 | Strong but not weak AHR agonist exhibits antiviral effect against DENV NGC2 in Huh7.5.1 cells. Huh7.5.1 cells were plated then, 24 h later,
treated with AHR agonist suspended in DMSO vs. DMSO alone, at indicated concentration, with or without submaximal dose IFN (25 IU/ml), for 24 h. Cells were then
infected with DENV NGC2 at MOI of 1, followed by 48 h incubation, then fixation, permeabilization, and staining for DENV, followed by quantitative microscopy for cell
counts and percent infected cells. Fold infection, vs. mock-treated cells, is shown. For the WEAK AGONIST (ITE), 0 um concentration, the % infected cells for three
unique experiments were 18, 29, 40. For the STRONG AGONIST (FICZ), 0 um concentration, the % infected cells for three unique experiments were 20, 30, 32.
Treatment groups are: (A) Weak agonist (ITE), no IFN. (B) Weak agonist (ITE), submax IFN. (C) Strong agonist (FICZ), no IFN. (D) Strong agonist (FICZ),
submaximal IFN. *p < 0.05 compared to control.
In this study, we have performed a targeted RNAi screen
seeking genes required for IFN to suppress both HCV
and DENV, leading to identification of 56 HCV/DENV
IEGs. These HCV/DENV IEGs included multiple nuclear
receptor interactors (HELZ2, MAP2K4, SLC27A2, HSP90AA1,
HSP90AA2), prompting further examination of IEG—nuclear
receptor interactions. HELZ2 target gene knockdown was
validated at the mRNA and protein levels, and IEG status
confirmed outside of screening conditions. Impact of IFN on
HELZ2 promoter and protein localization was then examined,
revealing that IFN activates both HELZ2 isoforms, and IFN
stimulation is associated with increased levels of nuclear HELZ2.
Lifecycles assays measuring effect of HELZ2 knockdown on
DENV via early-infection RNA ISH, qRT PCR, western blot,
immunofluorescence, and supernatant plaque assay reveal that
HELZ2 appears to exert anti-DENV activity from early infection
onward. In our prior study of HELZ2 effect on HCV, we
found that HELZ2 does not affect entry, as measured by a
pseudoparticle assay, but does affect post-entry lifecycle stages
(Fusco et al., 2013). While we have not performed DENV
pseudoparticle studies for direct comparison, overall our findings
for both DENV and HCV appear to be consistent in identifying a
role for HELZ2 in suppression of multiple viral lifecycle stages,
including production of viral RNA and protein production as
well as viral release. Because HELZ2 is a nuclear receptor co-
activator, we then sought to determine whether nuclear receptor
agonists themselves suppressed DENV. We initially examined
PPARα since potential antiviral and immunomodulatory activity
of PPARα agonists during viral infection have been reported
(Goldwasser et al., 2011; Sehgal et al., 2012), and PPARα agonists
have been reported to reverse IFN refractoriness during flaviviral
infection (Read et al., 2015). However, in our hands, agonists of
the NR PPARα decreased virus replication but only in the setting
of severe cytotoxicity.
We thus sought additional information to identify the NR
with which HELZ2 interacts during IFN stimulation, using
CHiP seq and high resolution lipid mass spectrometry. CHiP
seq revealed HELZ2 interaction (either direct or indirect) with
lipase maturation factor 1, whose gene product regulates TAG
metabolism through lipoprotein lipases (Peterfy, 2012), during
IFN stimulation. Metabolomic studies revealed that HELZ2
knockdown cells exhibit significant decrease of intracellular
triglyceride subsets. Because HELZ2 appears to regulate
triglycerides based on both CHiP seq and metabolomic data, we
hypothesized that IFN-stimulated HELZ2 activates a NR that
then alters triglyceride levels. Studies of mice with knockout
of the nuclear receptor AHR, a known immunoregulatory
nuclear receptor, have decreased triglycerides compared to wild
type controls (Minami et al., 2008). Furthermore, CHiP seq
experiments in MCF-7 human breast cancer cells treated with
the exogenous AHR agonist TCDD (2,3,7,8-tetrachlorodibenzo-
p-dioxin) identified AHR interactions with DNA from genes in
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FIGURE 9 | Primary bone marrow derived macrophages of HELZ2 knockout mice display enhanced DENV infectivity compared to wild type controls.
Age and sex matched HELZ2 knockout and WT mice were euthanized followed by isolation of primary bone marrow derived macrophages. Cells were plated in 96
well black clear bottomed plates then, the next day, treated with IFN or mock, then, the next day, infected with DENV NGC2, followed by 48 h incubation. Cells were
then fixed, permeabilized, stained, imaged, and analyzed for percent DENV infection. Graphs depict pooled data from three separate experiments which include a
total of 7 WT mice and 6 K/O mice. (A) Indicates DENV fold infection. (B) Indicates cell count per field. *p < 0.05 compared to control.
the triglyceride pathway (Lo and Matthews, 2012). In their study
of AHR DNA binding by CHiP seq, Lo et al. did not find that
AHR binds HELZ2 DNA, in human breast cancer cells (without
IFN stimulation; Lo and Matthews, 2012). However, they did
find that AHR binds to SLC27A2, which contains a known
AHRE (aryl hydrocarbon response element), and is another one
of our top IEG hits for both HCV and DENV (Fusco et al., 2013).
Furthermore, in both its liganded and non-liganded states, AHR
binds to the chaperone protein HSP90 (Hankinson, 1995; Meyer
and Perdew, 1999; Bell and Poland, 2000; Chang et al., 2014; Tsuji
et al., 2014), which also scored as a top IEG hit in both our HCV
and DENV screens. We therefore sought to determine whether,
in hepatocytes, HELZ2 and AHR might interact to mediate
IFN’s antiviral effects, and found that (1) AHR knockdown
led to weak but reproducible rescue of DENV from IFN, (2)
immunoprecipitation (IP) with anti-HELZ2 detected AHR,
and IP with anti-AHR detected HELZ2, and (3) a strong AHR
agonist (FICZ, formylindolo[3,2-b]carbazole) suppressed DENV
in the absence of cytotoxicity. FICZ is a tryptophan degradation
product, induced both by light- dependent and -independent
pathways (Smirnova et al., 2016), and an endogenous AHR
ligand (Wincent et al., 2009). Interestingly, a role for type I
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IFNs in tryptophan degradation has been well described, but has
not previously included FICZ. IFN beta induces indoleamine
2,3-dioxygenase (IDO), the enzyme responsible for tryptophan
degradation into kynurenine and other metabolites (not FICZ),
which have been implicated in IFN immune response, including
that observed during IFN treatment of multiple sclerosis (Meyer
et al., 1992; Durastanti et al., 2011). Furthermore, IDO activity
induced by IFN gamma has been described to have antiviral
properties against the DNA virus HSV-2 (Adams et al., 2004).
Consistent with these findings of IFN-mediated tryptophan
degradation, human sera from DENV infected patients have
been found to have increased levels of IDO mRNA expression
and IDO activity, compared to uninfected controls, eliciting the
hypothesis that IDO and tryptophan catabolism contribute to
the immune response to DENV infections in vivo (Becerra et al.,
2009).
In contrast to IDO, the enzymes responsible for converting
tryptophan into FICZ have not been reported to be IFN inducible.
Likewise, there are no prior reports, to our knowledge, citing
a direct role for IFN in FICZ production from tryptophan.
However, there have been reports of FICZ production in
skin affected by vitiligo (Schallreuter et al., 2012), a disease
characterized by IFN alpha hyperproduction (Bertolotti et al.,
2014). The mechanism through which FICZ might mediate
antiviral effects is also not clear, though it is possible that FICZ
binding to AHR prompts AHR translocation to the nucleus,
where it then interacts with HELZ2 to alter lipid related gene
activation. In support of this hypothesis, we found that FICZ
treatment, at doses with highest anti-DENV effect, does augment
a subset of TAGs which appear to be HELZ2 dependent. These
findings raise the possibility that, in response to IFN, HELZ2 is
upregulated and then the IEG HSP90 chaperones HELZ2 and
activated AHR to the nucleus where AHR activates the fatty acid
transporter/IEG SCL27A2 and the intracellular lipid/triglyceride
milieu is altered, potentially from a “proviral” to an “antiviral”
state. The AHR agonist FICZmay potentiate this antiviral process
by increasing nuclear levels of AHR, as engagement of FICZ and
other AHR ligands with AHR has been shown to prompt nuclear
translocation (Figure 3A of Kostyuk et al., 2012; Tsuji et al., 2014).
Future detailed studies of these HELZ2, SLC27A2, AHR, and
lipid-virus interactions, beyond the scope of this paper, will be
required to verify these hypotheses. Overall, our findings suggest
that there is a conserved set of genes required for IFN-mediated
suppression across at least two flaviviridae, enriched for nuclear
receptor interactors such as the ISG HELZ2, which appear to
modulate the intracellular triglyceride lipid milieu.
Limitations of our approach include the lack of an unbiased
search for HELZ2-NR interactions, which may have identified
additional NRs, and may have prompted discovery of more
potent antiviral compounds. For this reason, unbiased studies
of HELZ2 binding factors, in the presence and absence of
IFN, merit attention in future studies. However, we postulate
that the findings presented in this study do provide an
initial step toward a platform of IFN-derived HDAV discovery.
Refinement of this approach, including more extensive searches
for compounds that activate HELZ2/HELZ pathways are
likely to provide antiviral activity below the common viral
subversion point of STAT1/2. Such compounds will likely be
beneficial both for their antiviral activity and, perhaps equally
importantly, for their ability to help normalize cytokine signal
transduction during viral infections. Furthermore, the broad-
acting potential of IFN-related compounds may provide badly
needed placeholder solutions, pending distribution of more
definitive countermeasures, during epidemics of acute viral
infections. Finally, by defining key factors that dictate host IFN-
mediated control of viral infections, we may be able to identify
biomarkers to stratify clinical risk for viral pathology. Such
biomarkers might delineate virus infection, or reactivation, risk
posed by normal genetic variants as well as relative risk posed
by the increasing number of immunomodulatory biologic drugs
now progressing through clinical trials for treatment of diseases
such as malignancy and autoimmune disorders.
METHODS
Cell Culture
Huh7.5.1 hepatoma cells (a gift from F. Chisari, Scripps Research
Institute, La Jolla, CA.) and HeLa MAGI cells (a gift from A.
Brass, U. Mass. Worcester, Worcester, MA.) were maintained
at 37◦C in humidified air containing 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM;Cellgro) supplemented with
15% (volume/volume) fetal bovine serum (FBS;Gibco, #10437)
and 2 mM L-glutamine (Gibco). Medium was prepared on
a weekly basis to maintain maximum L-glutamine activity.
C636 mosquito salivary gland cells (ATCC CRL-1660) were
cultured in 10% EMEM (ATCC #30-2003) supplemented with
10% (volume/volume) fetal bovine serum (FBS; Gibco #10437)
and 2 mM L-glutamine (Gibco) with no antibiotics. Cells were
maintained at 28◦C with 5% CO2.
Virus Propagation
Dengue New Guinea C 2 was purchased from ATCC (ATCC
VR1584). Virus was propagated by inoculating C636 mosquito
cells with 1 ml viral stock for 1 h, followed by addition of
9 ml EMEM with 2% FBS with no antibiotics, at 28◦C. Viral
supernatant was harvested 4–8 days following inoculation, and
clarified by centrifugation at 1,500 rpm × 15 min at 4◦C.
Intracellular virus was harvested by scraping remaining cells
into 1 ml remaining medium, and then alternately exposing cell
mixture to dry ice and 37◦C water bath for periods of 5 min,
repeated 3–5 times, followed by centrifugation at 1,500 rpm ×
15 min and aliquoted for storage at−80◦C.
DENV IEG Screen
DENV IEG Screen was performed at the Harvard ICCB-L
Screening Facility. Four unique siRNA duplexes (siGenome,
Dharmacon) targeting each of 120 HCV IEGs (Fusco et al.,
2013) were arrayed in plate format. After quality control
testing (Z prime), screening was performed in 384 well
plate format. HeLa cells were reverse transfected with siRNA
using oligofectamine (Life Technologies 12252-011). Forty-eight
hours after transfection, transfection medium was removed by
aspiration and cells were treated with IFN 1,600 IU/ml. Twenty-
four hours following IFN treatment, IFN medium was removed
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by aspiration and cells were infected with DENV NGC2 at an
MOI of 1. Cells were then incubated for 48 h, followed by
fixation in 4% paraformaldehyde (Sigma), permeabilization in
0.2% Triton (Fisher BP151-500), then staining in primary anti-
dengue envelope antibody at 4◦C overnight (ATCC HB-114).
The following day, cells were rinsed, followed by staining in
secondary goat-anti-mouse antibody (Invitrogen A11001 Alexa
Fluor 488 goat anti mouse antibody) for 1 h at room temperature.
Cells were then rinsed followed by staining with Hoechst
anti-DNA stain (Sigma H6024). Plates were then imaged at
10X magnification on a Molecular Devices ImageXpress Micro
high-content screening microscope system, and analyzed using
MetaXpress technology for number of DENV-infected cells, total
number of cells, and calculation of percent infected cells.
Out-of-Screen Confirmation
Select DENV IEGs were confirmed out-of-screen. siGENOME
siRNA sets-of-four (upgrades) were purchased from
Dharmacon/GE Lifesciences and reverse transfections
performed, as described above, in HeLa and Huh7.5.1
hepatocytes.
Validation of siRNA Target Gene
Knockdown
For HELZ2 and AHR, knockdown of target gene product
was confirmed at the mRNA and protein level using qRT
PCR and western blot, respectively. For qRT PCR, HeLa cells
were reverse transfected in 24 well dishes, followed by RNA
isolation using QIAshreddor (Cat. 79654), then RNeasy RNA
isolation kit including genomic DNA eliminator columns (Cat.
74134). RNA was then reverse transcribed to DNA (Applied
Biosystems High Capacity cDNA reverse transcription kit,
#4368813), followed by qRT PCR using human TaqMAN probes
against HELZ2 (huHELZ2 Hs 00375699) and AHR (huAHR Hs
00169233), normalized using GAPDH huGAP (Hs 02758991).
For western blot, HeLa cells were reverse transfected in 24
well dishes followed by protein isolation using Cell Signaling
Protein Isolation buffer with PMSF, then protein quantification
using either Bradford or micro BCA method (Thermo Scientific
#23235), then western blot. Western blot quantification was
performed using image analysis software developed in our
laboratory, GELQuant, which is available to the public upon
request.
Total RNA Isolation and Quantitative RT
PCR (qRT-PCR)
Intracellular total cellular and viral RNA was isolated using
QIAshredderTM (Qiagen), followed by removal of genomic DNA
and RNA isolation using RNEasy plus kits (Qiagen), all according
to manufacterer’s protocols. RNA was stored at minus 80◦C,
then reverse transcribed by random priming using the High
capacity cDNA reverse transcription kit (Applied Biosciences)
and quantified by real-time PCR using the DyNAmo HS SYBR
green qPCR kit (Finnzyme;Espoo, Finland). qRT-PCR results
were interpreted using delta/delta CT (PMID 11328886), using
GAPDH as an internal control. Gene specific primers are
provided in Datasheet S5.
Western Blots
Drug Treatment
Cells were plated 24–48 h prior to drug treatment. When the
cells were confluent, they were given fresh medium containing
either 1,600 IU/mL interferon, 10 um fenofibrate (Sigma F6020),
or no drug as a negative control. The cells were incubated in their
respective medium at 37◦C for 24 h.
Protein Isolation
The cells were harvested using trypsin and pelleted at 500 g for
5 min. The pellets were then resuspended in ice-cold PBS and
pelleted again at 500 g for 5 min. Subcellular fractionation was
then performed using the Thermo Scientific Subcellular Protein
Fractionation Kit [product #78840] per the manufacturer’s
instructions. Protein samples were stored at minus 80◦C.
Western Blot
Protein concentration was determined by Bradford assay
kit (BioRad ##5000116). Twenty microliters of the least
concentrated sample was then used for western blot analysis; the
more concentrated samples were normalized to this first sample
such that the same amount of protein was loaded for each (20
ug). Deionized water was added as needed to bring each sample
volume to 20 uL. Samples were mixed with 7 uL NuPage sample
reducing agent and blue dye mixture and incubated for 10 min
at 80◦C to denature the proteins. Samples were then run on a
NuPage gel in 1x MES SDS running buffer at 180 V for 1 h,
with LifeTechnologies’ HiMarkTM Pre-Stained High Molecular
Weight Protein Standard.
A tank transfer onto nitrocellulose membranes was performed
using 1x NuPage Transfer buffer with 20% methanol at 4◦C and
30 V for 2 h. Membranes were then blocked for 1 h at room
temperature in 5% milk in 1x TBST. The membranes were then
cut horizontally and primary antibodies were added, in 5% milk
in 1x TBST.
Primary Antibodies
– Anti HELZ2, 1:1,000 (rabbit): abcam ab129781
– Anti Na+/K+ ATPase, 1:2,000 (rabbit) rabbit polyclonal,
abcam ab58475
Anti SP1, 1:2,000 (mouse) ms, abcam ab77441
– Anti β-actin, 1:10,000 (mouse) mc, ms, sigma A2228-2004 L
– Anti-tubulin, 1:2,000 (mouse) ms anti beta II tubulin abcam
Ab 28035
– Anti-histone H3, 1:80,000 (rabbit) rbt anti histone abcam
ab1791
Membranes were incubated with primary antibodies overnight
at 4◦C with gentle mixing. They were then washed 5 times for
5 min each wash at room temperature with gentle mixing in 1x
TBST. Following the washes, the membranes were blocked for 1
h at room temperature in their respective secondary antibodies
(see diagram above) at a concentration of 1:5,000 in 5% milk in
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1x TBST. Five more 5 min washes in 1x TBST were performed
prior to development.
ThermoScientific SuperSignal chemiluminescent substrate
was required to visualize HELZ2, SP1, and Na+/K+ ATPase.
For actin, tubulin, and histone H3, standard ThermoScientific
ECL substrate was used. Membranes were allowed to sit in their
respective substrate mixtures for 5 min before development.
Proteins were visualized on blue X-Ray films; for eachmembrane,
exposures of 2, 5, 10, 30 s and 2minwere performed.When bands
appeared were too dark for quantitative analysis even after 2 s,
repeat exposures were performed after allowing the membranes
to sit in the dark room for several minutes to allow luminescence
to fade.
Quantitative Analysis
Obtaining Images
Bands were scanned using an Epson scanner on the color photo
setting. Quantitative analysis was performed on the resulting
images using an original program. Each image was 3,504× 2,550
pixels with horizontal and vertical resolution each 300 dpi.
Determining Background Signal
Background color density was determined manually for each
scan by selecting a rectangular portion of the image that was
known not to have been exposed to any signal. Color density was
calculated by dividing the total color value of the region by the
area of the region.
Validating Bands
Rectangular regions containing bands were manually selected
from each scan for analysis. Each selected region was divided
by the program into rectangular subregions of equal width
containing the bands themselves. A vertical cross-section from
the center of each subregion was taken for manual analysis, and
the program plotted the color values for each pixel of the cross
section moving from top to bottom. In order to be considered
valid for quantitative analysis, a cross-section needed to display
a clear maximum color-value at some vertical coordinate; cross-
sections that rose to a color-value plateau instead were considered
to have saturated the X-Ray film’s capacity to accurately record a
signal and were quantified from a film developed with a shorter
exposure.
Quantifying Bands
For all bands considered quantifiable, the program moved from
left to right generating vertical cross-sections at every horizontal
coordinate. The program then determined the peak color-value
for each vertical cross section. These peak values were then
averaged to produce the final “signal” value for the band. These
signal values were assumed to correspond to the amount of
protein generating a given band and were used in analysis.
Normalization of Bands
HELZ2 signal values were normalized to their respective β–actin
signal values. For each compartment, the HELZ2:actin ratio for
the cells that received no drug treatment was considered to be
baseline, and the HELZ2:actin ratios for the interferon- and
fenofibrate-treated cells were normalized to the non-treated value
to produce fold-change values. Normalization was not performed
between compartments as β–actin is not necessarily expected
to be present in the same concentration in different subcellular
compartments.When three replicates of the experiment had been
performed, these fold-change values were averaged and standard
deviations of the mean were calculated for the interferon and
fenofibrate conditions. Fold-change values were not calculated
for the cytoskeleton as HELZ2 signal was not significantly above
background for these samples.
Bioinformatics
Screen hits were analyzed using Ingenuity Pathway Analysis
(IPA). HELZ2 promoter search for IFN stimulated response
elements (ISREs) was performed using the Position Specific
Scoring Matrix (PSSM) AGTTTCAGTTTC (Tsukahara et al.,
2006), and HOMER motif discovery software.
ISRE(IRF)/ThioMac-LPS-Expression(GSE23622)/Homer,
BestGuess:ISRE(IRF)/ThioMac-LPS-xpression(GSE23622)/
Homer(1.000) 10.512507−1.194927e+02 0
87179.0,1722.0,789.4,104.0,0.00e+00
0.653653653653654 0.001001001001001 0.229229229229229
0.116116116116116
0.008 0.288 0.676 0.028
0.001 0.003 0.001 0.995
0.001 0.027 0.001 0.971
0.001 0.001 0.025 0.973
0.003003003003003 0.975975975975976 0.019019019019019
0.002002002002002
0.583 0.007 0.24 0.17
0.0790790790790791 0.393393393393393 0.471471471471471
0.056056056056056
0.016 0.001 0.001 0.982
0.001 0.001 0.004 0.994
0.00899100899100899 0.044955044955045 0.003996003996004
0.942057942057942
0.001 0.881 0.01 0.108
FIMO discovered 3 ISREs in the Helz-Beta promoter at marginal
significance.
A p-value cutoff of 0.0001 was employed, and revealed 3 ISREs
in Helz2-beta promoter. No ISREs were discovered for Helz2-
alpha at p-value cutoff of 0.0001. The actual corrected p-values
(q-value, aka FDR) ranged from 0.143 to 0.581 (Datasheet S5).
These putative ISREs are highlighted in yellow in
Datasheets S2 and S5.
V$ISRE_01|2058 (+)|cAGTTTCGATTCtgg (q= 0.581).
V$ISRE_01|5166 (−)|tggAAAGTGAAATTg (q= 0.143).
HELZ2 Isoform Specific Promoter Reporter
Experiments
The unique promoter for each HELZ2 isoform was cloned
into a luciferase expression reporter. HELZ2 isoform-specific
promoter luciferase constructs 5′-flanking regions of the human
HELZ2 gene [−13,347/+25 base pairs (bp) of long isoform,
−19,832/+23 bp of short isoform] were inserted into KpnI/NheI
sites of the pGL4.10 luciferase reporter vector (Promega)
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employing a recombinant engineering strategy as previously
described (Liu et al., 2003; Tomaru et al., 2009). Sequence
information was obtained from the UCSC genome browser. The
reporter for each isoform was transfected into separate groups
of Huh7.5.1 hepatocytes or HeLa cells, followed by treatment
with IFN or drug, then luciferase development at indicated time
point.
Co-immunoprecipitation Protocol
Huh7.5.1 cells were plated in 10 cm dishes, incubated overnight,
then treated with mock, IFN 1,600 IU/ml, or 0.9 um FICZ.
Antibody Binding to Beads
Protein G beads (Novex by Life Technologies, #10003D, 30
mg/ml) and Protein A beads (Novex by Life Technologies,
#10001D, 30 mg/ml) were then prepared in quantity adequate
for 3.5 ul multiplied by (the number of samples multiplied by
number of Ab per sample + 0.5). For example, for two Ab, two
samples, 2 × 2 = 4 + 0.5 = 4.5 × 3.5 ul = 15.75 ul protein
G beads. Protein G and A beads were combined into a single
microfuge tube, followed by addition of 1 ml of 0.5% BSA,
then placement onto magnet. Bead mixture was then divided
into separate microfuge tubes for each antibody (500 ul/tube),
followed by addition of 500 ul more BSA to each tube. Ten
micrograms of appropriate antibody was then added to each tube
and samples placed at 4◦C shaker for 5–6 h. Antibodies used were
HELZ2 (abcam 129781), AHR (enzo BML-SA550-0100), and
isotype control (purified Armenian hamster IgG, eBiosciences #
14-4888-85).
Protein Isolation and Quantification
Each 10 cm dish was then rinsed in 1xPBS, trypsinized, then cells
centrifuged at 2,000 rpm for 5 min, followed by aspiration of
trypsin and pellet resuspension in cell signaling lysis buffer (190
ul dH20, 10 ul LB, 1 ul PMSF). Each sample was then incubated
on ice for 30 min with vortexing every 10 min. Samples were
then spun at 16,000 rcf at 4◦C for 10 min, followed by collection
of supernatant containing protein for further processing. Protein
samples, maintained at all times on ice, were then quantified by
the uBCA method.
Protein: Ab/Bead Incubation
Beads were then retrieved from 4◦C rotator, placed on magnet
and washed twice with 1 ml 0.5% BSA. Four hundred microliters
CHiP incubation buffer was then added to each tube, and 200 ul
of each Ab:bead mixture distributed to a new tube for incubation
with the appropriate protein sample. One hundred micrograms
of the appropriate protein was then added to each Ab:bead
mixture, followed by filling to 1,500 ul total volume per tube, with
CHiP incubation buffer. Samples were then incubated overnight
at 4◦C on shaker.
IP Complex Retrieval
The following morning, samples were retrieved from 4◦C, then
washed thrice for 5 min at 4◦C in 1x PBS with 0.5% triton x-100.
Beads were then replaced onto magnet, followed by aspiration of
wash, then addition of 100 ul Laemmli buffer (Laemmli-BOLT
LDS-#B0007 Novex), then heating to 100◦C for 8 min then
loading of 20 ul of each IP lysate for western blot. During wash
steps, original protein samples were retrieved from −80 and 20
ug prepared for gel loading (20 ug protein, filled to 13 ul with
H20, plus 2 ul 10X buffer, and 5 ul 4X SRA buffer), and heated to
100◦C for 8 min. Western blot was then processed as above.
CHiP Incubation Buffer
1% triton x-100, 2 mM EDTA, 150 mM NaCL, 20 mM tris-HCL,
pH 8.1.
AHR Agonist Treatment Experiments
ITE was obtained from Tocris (# 1803) and diluted to 10 um in
DMSO. FICZ was obtained from ENZO (# BML-GR206-0100)
and diluted to 0.3517 um in DMSO. Both reagents were stored
at −20◦C. Huh7.5.1 or HeLa cells were plated at 4,000 cells
per well in 96 well black clear bottomed plates (Corning Costar
#3603), followed 24 h later by treatment with AHR agonist with
or without IFN for 24 h, then addition of virus concentrate
(25 ul) on top of medium, then 48 h incubation, then fixation,
permeabilization, and staining for imaging/analysis for percent
infection.
Metabolite Extraction
Huh7.5.1 cells were plated in 10 cm dishes overnight then were
treated with mock or IFN 1,600 IU/l for 24 h, followed by harvest
of supernatant and cells for LC MS according to published
methods for Intracellular Metabolite Extraction/Lipid Method
(LPCs, LPEs, SMs, PIs, PEs, PCs, DAGs, TAGs) for 10 cm Dish
(Rhee et al., 2011, 2013). Huh7.5.1 cells were plated at∼7,500,000
Cells in a 10 cm plate. When ready for extraction, media was
siphoned, with aliquot of 1ml stored in respectively labeled tubes,
stored at−80◦C, followed by extraction protocol. Tenmicroliters
of conditioned media samples were deproteinized with 190 µl
Lipid IS-IS [isopropanol (Sigma-Aldrich) containing 10 µg/mL
of internal standards 17:1 Lyso-PC, 12:0, 13:0 PC, 17:0, 20:4
PC, and 20 µg/mL of 19:0 CE (Avanti)]. After vortexing, the
samples were centrifuged at 20,000 g at 4◦C for 15 min and
supernatants were transferred to HPLC quality glass vials with
inserts (MicroSolv).
Plates were gently immersed in optima grade HPLC H2O
(Fisher Chemical) for 1–2 s. H2O was then siphoned off. Plates
were then inverted (i.e., bottom-up), and Liquid Nitrogen poured
directly onto under-surface of plate using Liquid Nitrogen-
resistant basin. Liquid Nitrogen was then allowed to evaporate
(5–10 s). Plate was then turned and 5 ml of ice-cold 2-Propanol
(Fisher Chemical A461-212, Optima LC/MS) poured to evenly
cover surface of 10 cm plate, which was left for approximately 15
s. Samples were then aspirated 3 × 1.25 ml into 3, respectively,
labeled sample tubes (i.e., 3.75 ml total).
1.25 ml was then aspirated into collective (i.e., from each
plate) 15 ml tube (pooled lysate), and after mixing (i.e., inverting
and vortexing), 1.25 ml aspirated each into tubes labeled as
“PL (pooled lysate) 1, PL2” etc. (PLs were intermittently spaced
throughout the run to serve as a quality control). Samples were
then spun at 14,000 rpm × 10 min at 4◦C, then aliquotted in
aliquots of 1 ml into conical Eppendorf tubes, labeled as above,
transferred on dry ice, spun in a speedvac (Thermo Scientific) to
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dry down, and resuspended in 100 ul Lipid IS-IS. Finally, 65 ul
was then placed into glass tubes for mass spectrometry.
Metabolomic Profiling
Deproteinized extracts were subjected to reverse phase
chromatography using a HPLC C4 column (Grace) and
mobile phases [mobile phase A: 10 mM Ammonium Acetate:
Methanol: Acetic Acid (Sigma-Aldrich) (95:5:0.1, v:v:v); mobile
phase B: 0.1% Acetic acid in Methanol (Sigma-Aldrich)]. The
samples were injected directly onto the C4 column that was
eluted at a flow rate of 350 µL/min with initial conditions of 80%
mobile phase A and 20% mobile phase B for 2 min, followed by
a 1 min linear gradient to 20% mobile phase A, then a 12 min
linear gradient to 0% mobile phase A, maintained for 10 min,
then a 1 min linear gradient to 80% mobile phase A, maintained
for 9 min. Injection volume was 10 ul. The multiplexed liquid
chromatography (LC) system comprised of a 1,200 Series pump
(Agilent Technologies) and an HTS PAL autosampler (Leap
Technologies) equipped with two injection ports and a column
selection valve.
The LC system was connected to a 4,000 QTrap triple
quadropole mass spectrometer (Applied Biosystems/Sciex) run
in positive ion mode, in full scan mode (Q1 MS). MS analyses
were carried out using electrospray ionization (ESI).
Metabolite peaks were integrated using Sciex MultiQuant
software. All metabolite peaks were manually reviewed for
peak quality in a blinded manner. In addition, pooled
cellular extract samples were interspersed within each analytical
run at standardized intervals every 10 injections, enabling
the monitoring and correction for temporal drift in mass
spectrometry performance. The nearest neighbor flanking pair of
pooled plasma was used to normalize samples in a metabolite-by-
metabolite manner. Internal standard peak areas were monitored
for quality control and individual samples with peak areas
differing from the group mean by more than two standard
deviations were reanalyzed.
CHiP Seq
Huh7.5.1 cells were plated in 10 cm dishes at 80–90% confluence
then treated with IFN or mock for 24 h, followed by nuclear
extraction for CHiP seq.
Covaris Sonication and ChIP Protocol
Preblock and binding of antibody to magnetic beads. Dynal beads
were washed in block solution then resuspended in block solution
with antibody followed by overnight incubation at 4◦C. Beads
were then washed in block solution then resuspended in 0.5%
BSA/sample. Nuclei Preparation. Cross-linked cells were thawed
on ice, followed by isolation of nuclei using Covaris kit according
to manufacturer’s protocol, then shearing (Duty Cycle: 5%; Peak
Incident Power: 140 Watts; Cycles/Burst: 200, Temp: 4◦C). Post-
Shearing. Sheared samples were transferred into cold 1.5 mL Lo-
bind microcentrifuge tubes and centrifuged followed by transfer
of supernatant containing sheared chromatin to a new cold 1.5
mL Lo-bind tube, removal of∼50 µL for Whole Cell Extract and
storage at minus 20◦C, and removal of∼900 µL for IP or storage
at minus 80◦C. ChIP. Antibody/Bead Solution was then added
to each IP sample, followed by overnight incubation at 4◦C.
Crosslink Reversal: Beads were then precipitated with dynamag,
then washed with Low salt buffer + protease inhibitor then
High Salt buffer + protease inhibitor then 1X LiCl + protease
inhibitor then 1X TE Buffer + 50 mM NaCl (100 uL/10 ml)
followed by elution at 65◦C for 45 min, with vortexing every
5 min, then centrifugation (to spin down beads) then removal
of supernatant and transfer to new lo-bind microcentrifuge
tube, and reversal of crosslinks at 65◦C for 6 h. Digestion of
Cellular Protein and RNA was then performed using RNase A
followed by Proteinase K. DNA was then extracted with 400
µL Phenol:Chloroform:IsoamylOH. DNA concentrations were
measured with Qubit.
CHiP-Seq Sequencing and Analysis
Sequencing was performed on Illumina HiSeq 2,500 instrument,
resulting in ∼40 million single-end 50 bp reads per sample.
Reads were aligned against the hg19 reference genome using
BWA (Li and Durbin, 2009). Alignments were filtered for
uniquely mapped reads and alignment duplicates were removed.
Input-normalized coverage tracks were generated using SPP
(Kharchenko et al., 2008).
To identify potential protein binding sites, we determined
regions of ChIP-Seq tag enrichment. In brief, we analyzed tag
counts in a 1 Kb window over the chromosome length with the
step of 200 bp and estimated statistical significance of enrichment
of ChIP vs. input using negative binomial distribution, with the
estimate of themean based on the tag counts in input, and the size
parameter (s) selected based on manual inspection of resulting
peak calls. Regions of significant enrichment were generated by
merging adjacent significantly enriched windows separated by 1
Kb or less. In addition, we called broad regions of enrichment
using the peak caller SPP (Li and Durbin, 2009).
Since many of the peaks that were identified overlapped
with transcriptional start sites (TSSs), we also compared input-
normalized coverages over all annotated TSS ±1 Kb windows.
This resulted in the identification of additional regions of
enrichment not previously discovered through peak calling
alone.
Statistics
IEG hits were selected based upon 1.5x rescue of DENV infection,
compared to non-targeting control, on 2 or more plates, for
2 or more siRNA duplexes. Out-of-screen confirmation siRNA
transfection data was compared using means with standard error
of the means (SEM). qRT PCR data was analyzed using the δδCT
method, and data was compared usingmeans with SEM. Students
t-test (2 tailed, unequal variance) was used for determination of
statistical significance.
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